The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / For MAS, Early Diagnosis Is Key

For MAS, Early Diagnosis Is Key

November 1, 2010 • By Gretchen Henkel

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Thanks to research advances in the last decade, we now have a better understanding of the clinically dramatic and often devastating condition known as macrophage activation syndrome (MAS). As a result, says Alexei A. Grom, MD, associate professor of pediatrics at the Cincinnati Children’s Hospital Medical Center, “We are now learning how to watch for the early signs of this condition, treat those patients more aggressively, and prevent the progression of the syndrome to its life-threatening stage.”

You Might Also Like
  • The Key to Early Rheumatoid Arthritis
  • Macrophage Activation Syndrome
  • Pattern Recognition Key to Fibrosing Lung Disease Diagnosis
Explore This Issue
November 2010
Also By This Author
  • A Sporting Chance

In “Macrophage Activation Syndrome: Clinical Presentation and Disease Mechanisms,” presented at the 2009 ACR/ARHP Annual Scientific Meeting in Philadelphia, Dr. Grom outlined the advances in cellular immunology that are contributing to our increasing understanding of MAS. His copresenter, James Verbsky, MD, PhD, assistant professor of pediatrics and microbiology at the Medical College of Wisconsin in Milwaukee, offered two clinical cases that illustrated the diagnostic concepts that he and Dr. Grom discussed.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Features of the Syndrome

First described in 1979 and defined in 1985, MAS is a potentially fatal complication seen in several rheumatic conditions, including systemic erythematous lupus (SLE) and Kawasaki’s disease.1,2 However, it is most commonly found in systemic juvenile idiopathic arthritis (SJIA). The condition is characterized by excessive activation and proliferation of T cells and well-differentiated non-neoplastic macrophages, Dr. Grom explained. These macrophages exhibit hemophagocytic activity, which leads to a complete destruction of normal hemapoietic elements in the bone marrow. The three cardinal features of MAS are cytopenias, liver dysfunction, and coagulopathy consistent with disseminated intervascular coagulation (DIC). “MAS is also associated with massive systemic inflammation,” he added. “Presentation is often dramatic. Patients develop persistent fevers and impressive generalized lymphadenopathy and hepatosplenomegaly.” Hemorrhagic rash is also characteristic, starting with easy bruising and progressing to severe purpuric lesions and mucosal bleeding. The latter symptoms are found in late-stage disease, along with central nervous system dysfunction. A life-threatening condition, MAS is associated with a 20–30% mortality rate.

What Goes Awry?

“Clinically, MAS is very similar to familial hemophagocytic lymphohistiocytosis [FHLH], a constellation of rare diseases associated with genetic defects that lead to profound depression of cytolytic function of natural killer [NK] cells and cytotoxic CD8 lymphocytes,” Dr. Grom continued. Research has shown that diminished NK cell function in about 40% of FHLH patients is caused by mutations in the perforin gene (PRF1). This research has now yielded a bonus for MAS researchers, Dr. Grom noted, because similar cytolytic defects are seen in patients with SJIA and MAS.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Guidelines Tagged With: Diagnosis, Diagnostic Criteria, macrophage activation syndrome, MAS, TreatmentIssue: November 2010

You Might Also Like:
  • The Key to Early Rheumatoid Arthritis
  • Macrophage Activation Syndrome
  • Pattern Recognition Key to Fibrosing Lung Disease Diagnosis
  • Inflammatory Origin of Fever Is Key to Diagnosis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)